Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Triplet therapy slows progression of advanced kidney cancer

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

8 Sep 2022

Leukemia drug successfully disrupts HER2-positive brain metastasis in animal studies

In animal studies led by researchers at Duke Cancer Institute, a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast cancer tumors from colonizing the brain.

30 Aug 2022

New anti-cancer drug candidate is absorbed through the lymphatic system rather than blood vessels

A team of University of Michigan researchers is developing a new anti-cancer drug that is absorbed through the gut's lymphatic system rather than blood vessels, potentially outmaneuvering the molecular signaling pathways that lead to drug resistance while increasing cancer-fighting ability and reducing side effects.

17 Aug 2022

Pigment epithelium-derived factor ablations may lead to eye aging

Researchers identified that loss of pigment epithelium-derived factor (PEDF) may cause aging in the eye.

21 Jul 2022

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Researchers introduced a phenotypic screening assay for identifying compounds with SARS-CoV-2 inhibition potential based on caspase 3/7 activation.

20 Jul 2022

The known and proposed interactions of SARS-CoV and SARS-CoV-2 with DNA damage response pathways

Researchers reviewed the consequences of infection with sSARS-CoVs on the host DNA damage response.

19 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

24 Jun 2022

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.

20 Jun 2022

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

18 May 2022

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells.

19 Apr 2022

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

30 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Researchers investigated the efficacy of two multi-kinase inhibitors, olverembatinib and ponatinib, in inhibiting SARS-CoV-2 omicron-mediated cytokine release in human peripheral blood mononuclear cells.

10 Feb 2022

Study provides atomistic level insight into target residence time of small molecule kinase inhibitors

When a drug molecule binds to its target protein, it stays bound for some time before eventually unbinding the target. The actual time how long a drug molecule resides bound to its target varies among compounds.

29 Jan 2022

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations.

5 Jan 2022

Potential association between senescence and aging in COVID-19

A review published in Cells discussed characteristics of cellular senescence and its potential role in COVID-19.

9 Dec 2021

Clearing old, dysfunctional cells in fat alleviates diabetes

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from UConn Health report. The discovery could lead to new treatments for Type 2 diabetes and other metabolic diseases.

22 Nov 2021